LON:CREO Creo Medical Group (CREO) Share Price, News & Analysis → AI “wealth window” is closing soon! (From Paradigm Press) (Ad) Free CREO Stock Alerts GBX 35 +0.75 (+2.19%) (As of 04:17 PM ET) Add Compare Share Share Today's Range 34▼ 3550-Day Range 29.55▼ 39.5052-Week Range 22.72▼ 50Volume79,079 shsAverage Volume791,046 shsMarket Capitalization£126.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Creo Medical Group alerts: Email Address Ad Paradigm PressCould Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Creo Medical Group Stock (LON:CREO)Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.Read More CREO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CREO Stock News HeadlinesApril 9, 2024 | uk.finance.yahoo.comBlackRock Greater Europe Investment Trust Plc - Total Voting RightsMarch 11, 2024 | lse.co.ukGlobalworth Real Estate sells logistics portfolio for EUR70 millionApril 17, 2024 | Paradigm Press (Ad)AI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.March 11, 2024 | theglobeandmail.comVancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes offFebruary 20, 2024 | bizjournals.comHouston developer picks Medical Center for next 'flexible office' outpostFebruary 17, 2024 | morningstar.comCreo Medical Group PLCFebruary 12, 2024 | finance.yahoo.comCreo Medical Group expands reach of Speedboat UltraSlim; announces tie-up with Abu Dhabi universityFebruary 12, 2024 | finance.yahoo.comCreo Medical ends "pivotal" 2023 year with clear path to cashflow breakevenApril 17, 2024 | Paradigm Press (Ad)AI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.February 3, 2024 | msn.com10 physicians at Conemaugh Physician Group furloughedFebruary 1, 2024 | tmcnet.comCreo Engine Listed on Binance-Powered Tokocrypto, Indonesia's Leading Digital Assets PlatformJanuary 31, 2024 | lse.co.ukTRADING UPDATES: Creo unveils product in APAC; Unilever hires directorJanuary 29, 2024 | ca.finance.yahoo.comCreo Medical Group PLC (CREO.L)January 28, 2024 | finance.yahoo.comWith 67% ownership of the shares, Creo Medical Group PLC (LON:CREO) is heavily dominated by institutional ownersJanuary 10, 2024 | proactiveinvestors.comProactive news headlines: Creo Medical, Cornerstone, Seeing Machines, Belvoir, and moreNovember 27, 2023 | proactiveinvestors.comExpert view on Creo's techNovember 27, 2023 | finance.yahoo.comCreo Medical Group reveals good growth prospects at Capital Markets Day - Proactive Research AnalystNovember 15, 2023 | morningstar.comCreo Medical Group PLC CREONovember 13, 2023 | finance.yahoo.comInvestors in Creo Medical Group (LON:CREO) have unfortunately lost 82% over the last five yearsNovember 10, 2023 | bizjournals.com2023 Fast 50 Awards: No. 45 – CreoOctober 30, 2023 | msn.comCreo Medical to launch UltraSlim device 18 months ahead of scheduleOctober 4, 2023 | finance.yahoo.comBullish Creo Medical Group Insiders Loaded Up On UK£2.1m Of StockSeptember 16, 2023 | thetimes.co.ukShare tip: Innovation puts Creo Medical on a healthy trajectorySeptember 12, 2023 | lse.co.ukCreo Medical hails Speedboat Inject device as interim loss narrowsSeptember 12, 2023 | msn.comWelsh med tech firm posts big revenue rise following £33m fundraiseAugust 28, 2023 | uk.finance.yahoo.comHere’s how I’d aim to build a powerful second income portfolio with just £20,000August 21, 2023 | finance.yahoo.comOwning 47% shares,institutional owners seem interested in Creo Medical Group PLC (LON:CREO),See More Headlines Receive CREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Creo Medical Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/23/2020Today4/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:CREO CUSIPN/A CIKN/A Webcreomedical.com Phone+44-1291-606005FaxN/AEmployees279Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-25,040,000.00 Net Margins-85.54% Pretax MarginN/A Return on Equity-38.49% Return on Assets-19.98% Debt Debt-to-Equity Ratio13.33 Current Ratio4.13 Quick Ratio2.19 Sales & Book Value Annual Sales£29.27 million Price / Sales4.23 Cash FlowGBX 14.09 per share Price / Cash Flow2.43 Book ValueGBX 26 per share Price / Book1.32Miscellaneous Outstanding Shares361,480,000Free FloatN/AMarket Cap£123.81 million OptionableNot Optionable Beta0.84 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Craig Jonathan Gulliford (Age 54)CEO & Executive Director Comp: $472.66kProf. Christopher Paul Hancock (Age 57)Founder, CTO & Executive Director Comp: $360.17kMr. Richard John Rees ACA (Age 48)CFO, Company Secretary & Executive Director Comp: $359.8kMr. David Gerard Woods (Age 59)Chief Commercial Officer & Executive Director Comp: $446.38kMr. Phil HalesSales & Marketing DirectorKey CompetitorsEKF DiagnosticsLON:EKFNovacytLON:NCYTNIOX GroupLON:NIOXMaxCyteLON:MXCTAnimalcare GroupLON:ANCRView All Competitors CREO Stock Analysis - Frequently Asked Questions How have CREO shares performed in 2024? Creo Medical Group's stock was trading at GBX 46 on January 1st, 2024. Since then, CREO shares have decreased by 23.9% and is now trading at GBX 35. View the best growth stocks for 2024 here. How were Creo Medical Group's earnings last quarter? Creo Medical Group PLC (LON:CREO) posted its quarterly earnings results on Wednesday, September, 23rd. The company reported ($6.00) earnings per share for the quarter. Creo Medical Group had a negative trailing twelve-month return on equity of 38.49% and a negative net margin of 85.54%. What other stocks do shareholders of Creo Medical Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Creo Medical Group investors own include MySQUAR (MYSQ) and IQE (IQE). How do I buy shares of Creo Medical Group? Shares of CREO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:CREO) was last updated on 4/17/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsOptions trading has suddenly become more reliable.Eagle PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Creo Medical Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.